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Edited by Barry HalliwellAbstract The resolution of inﬂammation is dependent on
recognition and phagocytic removal of apoptotic cells by
macrophages. Receptors for apoptotic cells are sensitive to
degradation by human neutrophil elastase (HNE). We show in
the present study that HNE cleaves macrophage cell surface
CD14 and in so doing, reduces phagocytic recognition of
apoptotic lymphocytic cells (Mutu 1). Using an improved
method of adenovirus-mediated transfection of macrophages
with the HNE inhibitor elaﬁn, we demonstrate that elaﬁn
overexpression prevents CD14 cleavage and restores apoptotic
cell recognition by macrophages. This approach of genetic
modiﬁcation of macrophages could be used to restore apoptotic
cell recognition in inﬂammatory conditions.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The removal of cells undergoing apoptosis or programmed
cell death is an essential step in the resolution phase of the
inﬂammatory response. Macrophages are particularly impor-
tant in the processes of recognition and engulfment of apop-
totic cells [1,2] and inﬂammatory mediators may impair these
processes prolonging inﬂammation and tissue injury. Human
neutrophil elastase (HNE) is a potent protease released by
neutrophils during acute inﬂammation and mediates both di-
rect tissue damage and the upregulation of pro-inﬂammatory
cytokines such as interleukin (IL-8) [3–5]. HNE has also re-
cently been demonstrated to impair apoptotic cell recognition
by cleaving the phosphatidylserine receptor (PSR) on the
surface of macrophages [6]. A variety of macrophage receptors
have been implicated in apoptotic cell recognition, such as the* Corresponding author. Fax: +44-1-31-650-4384.
E-mail address: jsallena@staﬀmail.ed.ac.uk (J.-M. Sallenave).
Abbreviations: HNE, human neutrophil elastase; 61D3, monoclonal
blocking antibody against CD14; IL, interleukin; Ad, adenovirus; Ad-
d1703, control (empty) adenoviral vector; PBS, phosphate-buﬀered
saline; PSR, phosphatidylserine receptor; TNFa, tumour necrosis
factor-a; GFP, green ﬂuorescent protein
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.08.008PSR and CD14 [6,7] and from these the former has been
shown to be inactivated by HNE in patients with pulmonary
inﬂammation [6]. Similarly, HNE has been shown to degrade
CD14 on the surface of human peripheral blood monocytes
and ﬁbroblasts [8,9].
We have chosen to focus the present study on CD14 and
reasoned that a strategy aiming at protecting CD14 from
cleavage by HNE would be beneﬁcial, favouring apoptotic cell
removal in an inﬂammatory environment. For that purpose,
we used an adenovirus (Ad) gene-transfer methodology in-
volving complexing a recombinant Ad with the cationic lipo-
some lipofectamine. Using this technique, we show that the
HNE-mediated cleavage of CD14 and ensuing impairment of
apoptotic cell recognition are inhibited by Ad-mediated over-
expression of human elaﬁn, a potent HNE inhibitor. Inhibitors
of HNE are thought to comprise part of the human innate
immune system. Elaﬁn [10,11] is a potent inhibitor of HNE
and proteinase 3 produced in the skin and airways, which is
upregulated in response to early inﬂammatory cytokines such
as tumour necrosis factor (TNF) and IL-1 [4]. Our group has
recently demonstrated elaﬁn as a multi-faceted molecule ex-
hibiting direct antimicrobial activity [12] and an inhibitory
eﬀect on NF-jB mediated inﬂammatory cytokine production
[13].
We demonstrate here for the ﬁrst time that human macro-
phages can be genetically reprogrammed to overexpress elaﬁn,
from an HNE-mediated inﬂammatory phenotype, associated
with apoptotic cell recognition deﬁciency, to a phagocytic
competent phenotype. These ﬁndings have implications for the
use of adenovirus in ex vivo applications of macrophages in
inﬂammatory disorders.2. Materials and methods
2.1. Reagents
HNE was obtained from Elastin Products (Owensville, MO). Re-
combinant elaﬁn was a gift from Dr. J. Fitton, Astra-Zeneca (Mac-
clesﬁeld, UK). The monoclonal blocking antibody against CD14 (mAb
61D3) hybridoma (IgGl mouse anti-human) was originally obtained as
a gift from J.D. Capra [14]. Penicillin G, streptomycin sulfate, and
Iscove’s modiﬁed DMEM were obtained from Life Technologies
(Paisley, UK). X-Vivo 10 serum free culture medium was obtained
from Cambrex Bio Science (Wokingham, UK). Falcon tissue culture
material was from A.&J. Beveridge (Edinburgh, UK). 6-well, 48-well
and 96-well tissue culture plates were obtained from Corning Costarblished by Elsevier B.V. All rights reserved.
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ma Chemicals (Poole, UK).
2.2. Adenovirus (Ad) constructs
The generation of El, E3 deleted Ad constructs Ad-elaﬁn and Ad-
dl703 (‘‘empty’’ Ad control) has been described previously [15,16].
2.3. Macrophage isolation and FACS analysis
Mononuclear cells were isolated from peripheral blood as follows:
freshly citrated blood was centrifuged at 400 g for 20 min and the
platelet-rich plasma supernatant was used to prepare autologous se-
rum by addition of CaCl2 (10 mM ﬁnal concentration). Leukocytes
were isolated after removal of erythrocytes by sedimentation using 6%
(w/v) dextran T500 in saline by fractionation on a discontinuous gra-
dient of isotonic Percoll solutions made in Ca2þ/Mg2þ-free phosphate-
buﬀered saline (PBS) (CMF-PBS). Percoll concentrations of 55%, 68%
and 79% were used and the leukocytes were centrifuged at 700 g for
20 min. Mononuclear cells were aspirated from the 55%/68% interface
and washed three times in CMF-PBS prior to culture. Monocytes were
enriched from the mononuclear fraction by selectively attaching them
to 6-well plates for 40 min at 37 C. Non-adherent lymphocytes were
removed and adherent monocytes were washed twice in PBS. Mono-
cytes were then cultured in Iscove’s modiﬁed DMEM containing 10%
autologous serum, penicillin G (ﬁnal concentration 100 U/ml) and
streptomycin sulfate (ﬁnal concentration 100 lg/ml) at 37 C in a 5%
CO2 atmosphere. Maturation into macrophages with this culture
protocol has previously been demonstrated using myeloid-speciﬁc
markers, including CD16 and CD51/CD61 [17]. On culture day 4,
macrophages were removed with cold CMF-PBS and plated at 70 000
cells/well on 48-well plates in X-Vivo 10 serum free culture medium.
On culture day 6, Ad vectors were preincubated for 15 min at room
temperature in X-vivo 10 medium with lipofectamine (Invitrogen,
Paisley, UK) at a ratio of 5 104 lipofectamine molecules to each Ad
particle (Ad particle concentration was determined from absorbance at
260 nm for each Ad construct according to established protocols) and
added to day 6 macrophages at a multiplicity of infection (MOI) of
100. Macrophages were incubated in the virus-containing medium for
2 h before replenishment with X-vivo 10 growth medium.
Where indicated, HNE (1 lM) was added directly the following day
and incubated for 1 h prior to removal. Following HNE treatments,
cells were washed with ice cold CMF-PBS and suspended in 2% goat
serum (Serotec Ltd, Oxford, UK). Cells were incubated with 61D3, a
CD14 blocking monoclonal antibody [7], for 30 min, washed twice and
then incubated with phycoerythrin-conjugated goat anti-mouse IgG
secondary antibody for 15 min. Washed macrophages were then
analysed on a FACScan cytometer (Becton Dickinson and Co.).2.4. HNE inhibition assay
The HNE activity of macrophage supernatants, following incuba-
tion with HNE, was examined to determine any inhibitory eﬀect
conferred by infection with Ad-elaﬁn or incubation with r-elaﬁn. The
HNE activity assay has been described in detail elsewhere [18]. Brieﬂy,
all dilutions were performed in assay buﬀer (50 mM Tris, 0.5 M NaCl
and 0.1% Triton X-100, pH 8.0). Cell culture supernatant (90 ll) was
incubated in a 96-well microtitre plate for 30 min at 37 C before
addition of the chromogeneic substrate N-methoxysuccinyl–Ala–Ala–
Pro–Val–p-nitroanilide. The change in absorbance measured spectro-
photometrically at 405 nm (MR5000 Plate Reader, Dynatech, Dynex,
Billinghurst, UK) was expressed as a function of time. In a separate
experiment to measure HNE activity within apoptotic Mutu cells, two
independent batches of apoptotic Mutu cells (3 million cells) were
pelleted and washed with PBS and lysed in 0.4 ml of HNE buﬀer assay.
Cell lysate (50 ll) was added to a microtitre plate and HNE activity
recorded according to the protocol described above.Fig. 1. The eﬀect of HNE on surface expression of CD14 on human
macrophages. Where indicated, macrophages were incubated with
HNE (1 lM) for 1 h prior to removal. Binding of the 61D3 (anti-
CD14) antibody was then analysed by ﬂow cytometry. Adenovirus
infections were performed at an MOI of 100 using the protocol with
lipofectamine described in Section 2. (A) Uninfected cells. (B) Ad-
dl703-infected cells (MOI 100). (C) Ad-elaﬁn infected cells (MOI 100).
(D) Composite ﬁgure illustrating 61D3 binding in the diﬀerent con-
ditions from a separate donor. (E) Mean percent of macrophages
staining for CD14 S.D. Data are from experiments performed on
two separate donors.2.5. Apoptotic cells recognition assays
Macrophages were prepared and Ad infections performed in X-vivo
10 serum free medium as above in 48-well plates. Where indicated,
HNE (1 lM) and r-elaﬁn ð15 lg=ml ¼ 2:5 lMÞ were added directly for
1 h prior to the interaction assay with apoptotic cells. The group I
Burkitt lymphoma cell line Mutu I, induced into apoptosis by 16 h
incubation with 1 lg/ml of the calcium ionophore ionomycin (Cal-
biochem, Nottingham, UK), was used as a source of apoptotic cells.
Typically, around 70% of cells were apoptotic following this treatmentas determined by FACS analysis of annexin V staining. For some
experiments, the 61D3 CD14-blocking monoclonal antibody was
mixed with the apoptotic Mutu cells. The culture medium was removed
and 750 000 apoptotic Mutu cells were added to each 48-well for 1 h at
37 C before being washed extensively with ice cold CMF-PBS to re-
move unbound apoptotic cells. Cells were then ﬁxed in 1% parafor-
maldehyde and stained with Diﬀ-quick for counting. Cultures were
scored by light microscopy according to the proportion of macro-
phages that had internalised or bound apoptotic Mutu cells by
established criteria [7,19]. At least 300 macrophages were assessed
per sample.
2.6. Statistics
Results are presented as meansS.D. and diﬀerences between
treatments were tested using the Student’s t test.3. Results and discussion
Macrophages are important phagocytic cells involved in the
recognition and removal of apoptotic cells, integral processes
in the resolution of the inﬂammatory response [1,2]. Recent
data have suggested that HNE, a pro-inﬂammatory enzyme
released during uncontrolled inﬂammation [3], may be re-
sponsible for the impairment of apoptotic cell recognition by
macrophages, by cleaving key receptors on these cells [6]. The
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of other apoptotic cell recognition receptors, CD36 and CD32,
was relatively preserved. We have demonstrated that CD14, a
receptor with susceptibility to HNE, participates in the reso-
lution phase of the inﬂammatory response as a cell surface
receptor for apoptotic cells [7] in addition to acting as a re-
ceptor for bacterial lipopolysaccharide [20]. To test whether
HNE could cleave macrophage CD14, we treated this cell type
with puriﬁed HNE and analysed CD14 cell surface expression
by FACS analysis. Compared to untreated cells, HNE-treat-
ment drastically reduced the level of cell surface CD14
(Fig. 1A).
We decided to target HNE because of its deleterious action
in inﬂammatory conditions and its central role in cleaving a
variety of apoptotic cell receptors (CD14 and phosphatidyl-
serine [6] being two out of a list likely to grow). We designed a
gene therapy strategy to protect macrophages from the HNE-
mediated cleavage of surface receptors. Traditional gene
transfer vectors have proven disappointing for the transfection
of macrophages [21] and we have previously developed a hy-
brid method, involving pre-complexing of adenovirus with
cationic liposomes (lipofectamine) [13]. This method greatly
enhances transfection in other cell types both in vitro and in
vivo [22,23]. We have adapted this method for peripheral
blood monocyte-derived macrophages and show here an im-
pressive increase in transfection levels using green ﬂuorescent
protein (GFP) as a gene reporter (Fig. 2). Using this technique,
92% of macrophages exhibited GFP expression 24 h after in-
fection with Ad-GFP (counting in a low power ﬁeld). Simi-
larly, when macrophages were infected with Ad-elaﬁn/
lipofectamine, elaﬁn supernatant levels were increased from
10.4 (4.11) ng/ml with Ad-elaﬁn alone to 232 (13.1) ng/ml
(values are means and S.D. derived from a representative ex-
periment performed in triplicate). Elaﬁn was not detected in
the supernatant from uninfected cells. Having established the
disruptive activity of HNE on macrophage CD14 in our Sys-
tem (see above, Fig. 1A), we demonstrated that Ad-elaﬁn in-
hibited HNE-mediated shedding of CD14 compared to
macrophages infected with Ad-dl70/3, an Ad vector with noFig. 2. Lipofectamine facilitates Ad-GFP infection of macrophages.
Peripheral blood monocyte-derived macrophages were infected on
culture day 6 with Ad-GFP (100 PFU/cell). Where indicated, virus was
precomplexed with lipofectamine (+) according to protocols in Section
2. Photomicrographs were taken 24 h after Ad infection and GFP
ﬂuorescence was observed. (A) No ﬁlter and (B) green ﬁlter.transgene cassette (Fig. 1B and C). When serum-free super-
natants were tested for HNE activity, most HNE was inhibited
when a saturating concentration of r-elaﬁn was added extra-
cellularly (Fig. 3). Although Ad-elaﬁn was eﬃcient in pre-
serving CD14 expression, it conferred by contrast a relatively
modest, albeit signiﬁcant, inhibition of HNE when compared
to Ad-dl70/3 (Fig. 3). This result was predicted from the elaﬁn
concentrations in Ad-elaﬁn infected cell supernatants that were
theoretically not high enough to neutralise the quantity of
HNE added.
Finally, we investigated the eﬀect of HNE on macrophage
apoptotic cell recognition and whether Ad-elaﬁn had a pro-
tective role. A variety of cells, such as lymphocytes and neu-
trophils, are routinely used in experimental systems as
apoptotic target cells. We chose Group 1 Burkitt lymphoma
cells (Mutu I) over neutrophils because of the absence of en-
dogenous HNE in the former (HNE levels were below the
levels of detection from apoptotic mutu cell lysates, see Section
2), which could have interfered with our assays. Previous work
has demonstrated that binding of viable Mutu cells is negli-
gible in this system and any interaction that does occur is with
spontaneously apoptotic Mutu cells [19]. Macrophages were
either untreated/uninfected (control) or infected with Ad-elaﬁn
(Ad-dl70/3 as a control) and incubated where indicated with
HNE. In a variation of these experiments, the CD14 blocking
antibody 61D3 [7] was used in order to provide a positive
control of CD14 blockade. Fig. 4 shows that HNE treatment
of untransfected cells inhibited Mutu cell recognition by 54%,
compared to untransfected cells alone. This level of inhibition
was comparable to that of 61D3 treatment. The prominent
role of CD14 (the 61D3 antigen) for interaction and initial
tethering of apoptotic Mutu cells with human macrophages
has previously been characterised. Blocking antibodies andFig. 3. Comparison of HNE inhibitory activity of macrophage culture
supernatants. Macrophages were prepared and infected with Ad-vec-
tors using the protocols described in Fig. 1. Following incubation with
HNE, culture supernatants were removed for determination of residual
HNE activity. Supernatants were transferred to a microtitre plate and
cleavage of a chromogenic HNE substrate was measured spectropho-
tometrically over time. P values are given for the comparisons of Ad-
dl703 (control adenovirus) and uninfected cells to Ad-elaﬁn. Data are
means S.D. from experiments performed in triplicate on three sep-
arate donors ðn ¼ 3Þ.
Fig. 4. Elaﬁn protects macrophages from HNE-mediated impairment of Mutu cell recognition. Macrophages were cultured and infected with Ad
vectors using the same protocol from Fig. 1. Where indicated, HNE (1 lM) and r-elaﬁn (2.5 lM) were added in serum free X-vivo 10 medium for 1 h
prior to adding the apoptotic Mutu target cells with or without 61D3 (CD14 blocking monoclonal antibody). After ﬁxing and staining, the per-
centage of macrophages interacting with apoptotic Mutu cells was calculated. Interaction counts performed on macrophages that had not been
exposed to Mutu cells are also shown to exclude any signiﬁcant contribution from apoptotic cells originating from within the culture. P values are
given for each comparison. Data are meansS.D. from experiments performed in quadruplicate on three separate donors ðn ¼ 3Þ.
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CD36 produced little if any reduction of apoptotic Mutu cell
interaction in this system [19]. Interestingly, when 61D3 and
HNE were used in combination, a further decrease in recog-
nition occurred, suggesting that the sites of action of 61D-3
and HNE are not identical. It is likely that in addition to
cleaving CD14 (Fig. 1), HNE is interfering with additional
(unidentiﬁed) surface receptors in our system and notably the
degree of inhibition never approached 100% even with 61D3
and HNE together. HNE cleavage of the PSR was associated
with reduced ingestion of apoptotic Jurkat cells by human
macrophages [6] and the role of PSR cleavage in reducing in-
teraction in our system is unknown.
When r-elaﬁn was added extracellularly with HNE, macro-
phage recognition was restored to normal values. Similarly,
when macrophages were transfected with Ad-elaﬁn, prior to
HNE challenge, a very signiﬁcant increase in macrophage
recognition of apoptotic cells was obtained, compared to un-
transfected cells and cells transfected with Ad-dl70/3, demon-
strating the elaﬁn transgene speciﬁc eﬀect (Fig. 4). In addition,
Ad-transfection on its own (Ad-dl70/3 and Ad-elaﬁn) did not
inﬂuence apoptotic cell recognition. HNE, Ad-elaﬁn and Ad-
dl703 had no eﬀect alone on the background rate of apoptotic
cell recognition in the absence of apoptotic Mutu cells (Fig. 4;
2nd, 3rd and 4th bars from the left).
These results illustrate the potential of elaﬁn gene therapy to
rescue the capacity of macrophages to recognise apoptotic cells
in the presence of HNE. Although expression of CD14 was
relatively preserved in Ad-elaﬁn infected macrophages
(Fig. 1C), the eﬀect on residual supernatant HNE activity was
less marked (Fig. 3) indicating the possibility that elaﬁn may
facilitate apoptotic cell recognition through additional mech-
anisms. Indeed, we have shown that elaﬁn has broad ranging
anti-inﬂammatory properties, inhibiting the action of the
transcription factor NF-jB and the release of pro-inﬂamma-
tory cytokines such as TNF and IL-8 [13]. Since HNE has been
shown to have pro-inﬂammatory signalling eﬀects [4,5], it is
likely that the Ad-elaﬁn transfection of macrophages provides
a further anti-inﬂammatory signal beneﬁcial to apoptotic cellrecognition. This signal would reinforce the endogenous anti-
inﬂammatory phenotype conferred by binding of apoptotic
cells to macrophages [24] that may otherwise be diminished by
HNE. Interestingly, the endogenous synthesis of another
neutrophil elastase inhibitor, secretory leukocyte protease in-
hibitor (SLPI), has recently been shown to be up-regulated
following macrophage recognition of apoptotic cells [25].
However, as pointed out by Odaka et al. [25], the slow kinetics
of production of SLPI after the apoptotic cell recognition
event suggests that SLPI is unlikely to act in vivo at an au-
tocrine level during the onset of the interaction but rather in a
paracrine fashion, during phagocytosis of incoming cells.
In summary, we show here that using adenovirus as a gene
transfer vector in a hybrid method with lipofectamine as a
facilitating agent, it is possible to very eﬃciently transfect
monocyte-derived macrophages ex vivo with elaﬁn, a potent
elastase inhibitor. This rescues these cells from an HNE-in-
duced pro-inﬂammatory to an anti-inﬂammatory phenotype
favouring apoptotic cell recognition and clearance. The po-
tential for systemic delivery of macrophages transfected ex
vivo with antinﬂammatory genes has been demonstrated in
murine glomerulonephritis [26,27] and this methodology may
prove useful in inﬂammatory conditions where direct use of
adenovirus gene vectors is precluded, because of their intrinsic
immunogenicity. Cystic ﬁbrosis, characterised by an excessive
load of unchecked HNE and a recognised ‘‘paralysis’’ of innate
immune mechanisms [28], provides a fascinating model in
which to test this paradigm.Acknowledgements: The authors thank the Edinburgh University
Wellcome Trust Cardiovascular Research Initiative for providing a
Clinical Training Fellowship to P.A.H.References
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